Dyslipidemia: evidence of efficacy of the pharmacological and non-pharmacological treatment in the elderly

( views:542, downloads:0 )
Author:
Claudia F Gravina(Geriatric Cardiology Section, Dante Pazzanese Institute of Cardiology,Avenida Dr Dante Pazzanese 500, Ibirapuera , S(a)o Paulo 04012-180, Brazil)
Marcelo Bertolami(Dante Pazzanese Institute of Cardiology, Scientific Division, Av. Dr. Dante Pazzanese 500, Ibirapuera, Sao Paulo 04012-180, Brazil)
Giselle HP Rodrigues(Heart Institute-INCOR, University of S(a)o Paulo Medical School, Rua Ministro Godoi,1186, Apartment 12, Perdizes, S(a)o Paulo 05015-001, Brazil)
Journal Title:
JOURNAL OF GERIATRIC CARDIOLOGY
Issue:
Volume 09, Issue 02, 2012
DOI:
10.3724/SP.J.1263.2011.12292
Key Word:
Elderly patient;Risk factors;Dyslipidemia;Cardiovascular disease;Diet

Abstract: The clinical decision to control risk factors for cardiovascular disease (CVD) in the elderly takes the followings into consideration: (1) the elderly life expectancy; (2) the elderly biological age and functional capacity; (3) the role of cardiovascular disease in the elderly group; (4) the prevalence of risk factors in the elderly; and (5) The effectiveness of treatment of risk factors in the elderly. A large number of studies showed the efficacy of secondary and primary prevention of dyslipidemia in the elderly. However, the only trial that included patients over 80 years was the Heart Protection Study (HPS). Statins are considered the first line therapy for lowering low-density lipoprotein cholesterol (LDL-C). Because lifestyle changes are very difficult to achieve, doctors in general tend to prescribe many drugs to control cardiovascular risk factors. However, healthy food consumption remains a cornerstone in primary and secondary cardiovascular prevention and should be implemented by everyone.

  • [1]Http//www.ibge.gov.br (accessed on November 6,2011).
  • [2]Http:www.ibge.gov.br/home/presidência/noticia_visualiz.ph p?id_noticia_150 (accessed on November 3,2011).
  • [3]National Center for Health Statistics.Third National Health and Nutrition Examination Survey 1988–1994,US NHANES III Examination Data File,1996.Http//www.cdc.gov/nchs/ nhanes/nh3data.htm (accessed on April 22,2012).
  • [4]Lavie CJ.Assessment and treatment of lipids in elderly persons.Am J Geriatr Cardiol 2004;13:2–3.
  • [5]Catapano AL,Reiner Z,De BG,et al.ESC/EAS Guidelines for the management of dyslipidaemias:the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).Atherosclerosis 2011;217 (Suppl 1):S1–S44.
  • [6]van Oostrom O,Velema E,Schoneveld AH,et al.Agerelated changes in plaque composition:a study in patients suffering from carotid artery stenosis.Cardiovasc Pathol 2005;14:126–134.
  • [7]Gravina Taddei CF,Ramos LR,Moraes JC,et al.Multicenter study of out-patients elderly in Brazil.Arq Bras Cardiol 1997;69:327–333.
  • [8]Baigent C,Blackwell L,Emberson J,et al.Efficacy and safety of more intensive lowering of LDL cholesterol:a meta-analysis of data from 170,000 participants in 26 randomised trials.Lancet 2010;376:1670–1681.
  • [9]Shao H,Chen LQ,Xu J.Treatment of dyslipidemia in the elderly.J Geriatr Cardiol 2011;8:55–64.
  • [10]Gravina CF,Rosa RF,Franken RA,et al.II Brazilian Guidelines of Geriatric Cardiology.Department of Geriatric Cardiology,Brazilian Society of Cardiology.Arq Bras Cardiol 2010;95 (3 Suppl 2):S1–S112.
  • [11]Miettinen T,Pyorala K,Olsson A,et al.Cholesterol-lowering theraphy in women and elderly patients with myocardial infarction or angina pectoris.Findings from the Scandinavian Simvastatin Survival Study (4S).Circulation 1997;96:4211–4218.
  • [12]Lewis S,Moye L,Sacks F,et al.Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range.Results of the Cholesterol and recurrents events (CARE) trial.Ann Intern Med 1998;129:681–689.
  • [13]Rubins HB,Robins S,Collins D,et al.Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.N Engl J Med 1999;341:410-418.
  • [14]MRC/BHF Heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals:a randomised placebo-controlled trial.Lancet 2002;360:7–22.
  • [15]Shepherd J,Blauw G,Murphy M,et al.Pravastatin in elderly individuals at risk of vascular disease (PROSPER):a randomised controlled trial.Lancet 2002;360:1623–1630.
  • [16]Cannon CP,Braunwald E,McCabe CH,et al.Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes.N Eng J Med 2004;350:1495–1504.
  • [17]PROVE-IT TIMI 22:Large benefit in elderly ACS patients treated to low LDL cholesterol levels.http:www.theheart.org/ article/404557 (accessed on November 6,2011).
  • [18]LaRosa J,Grundy S,Waters D,et al.Intensive lipid lowering with atorvastatin in patients with stable coronary disease.N Engl J Med 2005;352:14.
  • [19]Deedwania P,Stone P,Merz NB,et al.Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease:Results of the Study Assessing Goals in the Elderly (SAGE).Circulation 2007;115:700–707.
  • [20]Ridker PM,Danielson E,Fonseca FA,et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med 2008;359:2195–2207.
  • [21]Grundy S,Cleeman J,Merz C,et al.Implications of recent clinical trial for the national cholesterol education program adult treatment panel III guidelines.Circulation 2004;110:227–239.
  • [22]Lemaitre R,Psaty B,Heckbert S,et al.Therapy with hydroxymethylglutary Coenzime A reductase inhibitors (Statins) and associated risk of incident cardiovascular events in older adults.evidence from the cardiovascular health study.Arch Intern Med 2002;162:1395–1400.
  • [23]Grundy S,Cleeman J,Merz C,et al.Implications of recent clinical trial for the national cholesterol education program adult treatment panel III guidelines.Circulation 2004;110:227–239.
  • [24]Gordon T,Castelli WP,Hjortland MC,et al.High density lipoprotein as a protective factor against coronary heart disease.The Framingham Study.Am J Med 1977;62:707–714.
  • [25]deGoma EM,Leeper NJ,Heidenreich PA.Clinical significance of high-density lipoprotein cholesterol in patients with low low-density lipoprotein cholesterol.J Am Coll Cardiol 2008;51:49–55.
  • [26]Barter PJ,Caulfield M,Eriksson M,et al.Effects of torcetrapib in patients at high risk for coronary events.N Engl J Med 2007;357:2109–2122.
  • [27]Davidson MH,McKenney JM,Shear CL,et al.Efficacy and safety of Torcetrapib,a novel cholesteryl ester transfer protein inhibitor,in individuals with below-average high-density lipoprotein cholesterol levels.J Am Coll Cardiol 2006;48:1774–1781.
  • [28]Cannon CP,Shah S,Dansky HM,et al.Safety of Anacetrapib in patients with or at high risk for coronary heart disease.N Engl J Med 2010;363:2406–2415.
  • [29]Stroes ES,Nierman MC,Meulenberg JJ,et al.Intramuscular administration of AAV1-lipoprotein lipase S447X lowers tryglicerides in lipoprotein lipase-deficient patients.Arterioscler Thromb Vasc Biol 2008;28:2303–2304.
  • [30]Stein EA,Roth EM,Rhyne JM,et al.Safety and tolerability of dalcetrapib:results from a 48 week trial.Eur Heart J 2010;31:480-488.
  • [31]Bloomfield D,Carlson GL,Sapre A,et al.Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministred with atorvastatin in dyslipidemic patients.Am Heart J 2009;157:352–360.
  • [32]Mehta N.Fellow′s corner:residual cardiovascular risk and HDL the year in review,2012.Http://www.medscape.org/ viewarticle/758440 (acessed on January 10,2012).
  • [33]Steinberg D.Thematic review series:the pathogenesis of atherosclerosis.An interpretive history of the cholesterol controversy:Part I.J Lipid Res 2004;45:1583–1593.
  • [34]Steinberg D.Thematic review series:the pathogenesis of atherosclerosis.An interpretive history of the cholesterol controversy:Part II:the early evidence linking hypercholesterolemia to coronary disease in humans.J Lipid Res 2005;46:179–190.
  • [35]Getz GS,Reardon CA.Nutrition and cardiovascular disease.Arterioscler Thromb Vasc Biol 2007;27:2499–2506.
  • [36]de LM,Salen P,Martin JL,et al.Mediterranean diet,traditional risk factors,and the rate of cardiovascular complications after myocardial infarction:final report of the Lyon
  • [37]Steinberg D.Thematic review series:the pathogenesis of atherosclerosis:an interpretive history of the cholesterol controversy,part III:mechanistically defining the role of hyperlipidemia.J Lipid Res 2005;46:2037–2051.
  • [38]Diet Heart Study.Circulation 1999;99:779–785.
  • [39]Breslow JL.n-3 fatty acids and cardiovascular disease.Am J Clin Nutr 2006;83(6 Suppl):S1477–S1482.
  • [40]Leaf A.Prevention of sudden cardiac death by n-3 polyunsaturated fatty acids.J Cardiovasc Med (Hagerstown) 2007;8 (Suppl 1):S27–S29.
  • [41]Marchioli R,Barzi F,Bomba E,et al.Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction:time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.Circulation 2002;105:1897–1903.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn